{
    "nct_id": "NCT04866134",
    "official_title": "A Phase 1b/2, Open-label, Multi-center Study of ERAS-007 (ERK Inhibitor) Administered as Monotherapy or in Combination With ERAS-601 (SHP2 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors (HERKULES-1)",
    "inclusion_criteria": "* Age â‰¥ 18 years.\n* Willing and able to give written informed consent.\n* Have histologically or cytologically confirmed advanced or metastatic solid tumor with a relevant molecular alteration (as applicable).\n* There is no available standard systemic therapy available for the patient's tumor histology and/or molecular biomarker profile; or standard therapy is intolerable, not effective, or not accessible; or patient has refused standard therapy.\n* Recovered from all toxicities associated with prior treatment to acceptable baseline status.\n* Have ECOG performance status of 0 or 1 with an anticipated life expectancy of > 12 weeks.\n* Willing to comply with all protocol-required visits, assessments, and procedures.\n* Able to swallow oral medication.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Currently receiving another study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of ERAS-007.\n* Received previous treatment with an ERK inhibitor.\n* For participants being considered for ERAS-007 + ERAS-601 (Part D): prior treatment with SHP2 inhibitor.\n* For participants being considered for ERAS-007 + ERAS-601 (Part D): documented PTPN11 mutations\n* Received prior antineoplastic therapy within < 21 days or 5 half-lives, whichever is shorter.\n* Received prior palliative radiation within 7 days of first dose of ERAS 007 or ERAS-601,\n* Received previous treatment with a MAPK inhibitor that resulted in discontinuation due to unacceptable toxicity.\n* Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption.\n* Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs.\n* Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial.",
    "miscellaneous_criteria": ""
}